Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes

Trial Profile

Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 May 2017

At a glance

  • Drugs MLE 4901 (Primary)
  • Indications Hot flashes
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 15 May 2017 According to a Millendo Therapeutics media release, data from this study will be presented at the 19th European Congress of Endocrinology (ECE).
    • 03 Apr 2017 Results published in a Millendo Therapeutics media release.
    • 03 Apr 2017 Results presented at the annual meeting of The Endocrine Society (ENDO 2017), according to a Millendo Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top